Kornimate/medical-research-clean huggingface dataset:
a study to learn about venous thromboembolism (vte) treatment with rivaroxaban in japanese patients using a claims database

Conditions: Treatment of Venous Thromboembolism

Summary: this is an observational study in which data from the past is collected for a treatment which is already available for doctors to prescribe for venous thromboembolism (vte). vte is a condition in which blood clots form in veins, which can lead to disability and death. this study looks at the bleeding risk in japanese patients who are already receiving long-term rivaroxaban treatment for their vte. some common causes of vte are surgery, lack of movement, being bed-ridden and cancer. vte that is caused by cancer is called cancer-associated venous thromboembolism (ca-vte). the study treatment, rivaroxaban, is a blood thinner prescribed by doctors to help treat conditions like vte. by thinning the blood, rivaroxaban can help keep blood flowing normally and prevent blood clots. but, rivaroxaban can lead to increased bleeding in some people. there have been studies done in which participants with vte and ca-vte received treatment with rivaroxaban for a long period of time. the overall results of those studies showed that long-term treatment with rivaroxaban helped prevent blood clots in those participants. some of the participants had increased bleeding after this long-term treatment, while some did not. participants with certain types of cancers, such as ca-vte, also had an increased risk of bleeding. these studies, however, did not include japanese participants. so, the researchers in this study want to learn more about the risk of bleeding in japanese patients with vte or ca-vte who receive long-term treatment with rivaroxaban. to do this, the researchers plan to use a medical database to find information for patients with vte and ca-vte who have already been taking rivaroxaban for their condition. this database will help the researchers collect information about the bleeding risk of long-term rivaroxaban treatment in japanese patients. in this study, the researchers will learn more about: * the characteristics of patients with vte who are treated with rivaroxaban for a period of less than 3 months to more than 1 year * the bleeding risk for all of the patients throughout the study * the bleeding risk for the patients with ca-vte throughout the study * the cause of any bleeding that happens the researchers will follow and record these results for japanese patients from october 2015 to december 2020.


Eligibility criteria:
inclusion criteria: * having a diagnosis of vte recorded during the selection period (01-apr-2016 to 31-may-2020 inclusive), * having a rivaroxaban prescription claim within 30 days after the vte diagnosis , * being age 18 years or older at the index date, * having at least 180 days baseline period. exclusion criteria: * having evidence of atrial fibrillation, atrial flutter, dialysis, cteph (chronic thromboembolic pulmonary hypertension) or pregnancy during the baseline period, * having a claim of rivaroxaban during the baseline period.
right ventricular outflow tract study

Conditions: Sinus-node Dysfunction

Summary: this is a prospective, randomized, double blinded, multi-center, controlled study to evaluate the clinical impact at 18 months after ddd implantation of alternative pacing site (rvots and rva) and the different conduction path (rvots and av node) on cardiac dysfunction prevention.

ventricular pacing is unavoidable in many patients because of unreliable or absent av conduction, or permanent af. in recognition of this need, interest has focused on alternative site(s) ventricular pacing to maximize pumping function. these sites include the rv septum, his bundle, various lv sites, and combination of lv and rv (biventricular \[biv\]). the rv outflow tract septum (rvots) seems to be the most promising site within the rv. however, small enrollment and inconsistent experimental methods hinder the interpretation of these studies. locations of alternative pacing sites were not clearly specified, were largely topographic, and lacked consistent anatomic designation. and what is more, there was no prospective, double-blind randomized, multi-center clinical trial which is design to test whether rvots pacing is superior to right ventricular apical pacing in preserving left ventricular systolic function and avoiding adverse left ventricular remodeling in patients with a normal left ventricular ejection fraction, ventricular synchrony and standard indications for pacing (sinus node dysfunction) in china. there was also no prospective, double-blind randomized, multi-center clinical trial which is design to test whether rvots pacing is not inferior to aair pacing in preserving left ventricular systolic function and avoiding adverse left ventricular remodeling in patients with a normal left ventricular ejection fraction, ventricular synchrony and sinus node dysfunction in the world. so sjm china will sponsor a prospective, randomized, double blinded, multi-center, controlled study to evaluate the clinical impact at 18 months after ddd implantation of alternative pacing site (rvots and rva) and the different conduction path (rvots and av node) on cardiac dysfunction prevention.

Eligibility criteria:
inclusion criteria: * patients with only sinus-node dysfunction and meet pacing indication * patients with lvef≥60% and with ventricular synchrony. * patients signed the written informed consent for the study * patients can endure the required follow up exclusion criteria: * patients with atrial fibrillation * patients with atrial-ventricular block * patients with lbbb * patients with significant valvular disease * patients with severe hematopathy or severe renal inadequacy * patients with life expectancy \< 1.5 year * patients who are in the period of pregnant or lactation * patients who are younger than 18 years old * patients who are ongoing other devices or agents study

Keywords: sinus-node dysfunction rvots pacing rva pacing
repeat dosing of psilocybin in migraine headache

Conditions: Migraine Headache

Summary: in seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. in seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured.

migraine headache is a common medical condition and a top cause of disability worldwide. treatment options for migraine headache are many and varied, though an approximated 10% of migraineurs is refractory to medication and thus, there is a need to develop alternative treatments. there is anecdotal evidence supporting lasting therapeutic effects after limited dosing of psilocybin and related compounds in headache disorders. the cause of this unique effect remains unknown, though the drug class has demonstrable anti-inflammatory activity, a biological process relevant to migraine and other headache disorders. in seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. in seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured. the results from this study will serve in the development of larger investigations seeking to understand the effects of psilocybin and related compounds in headache disorders.

Eligibility criteria:
inclusion criteria: * diagnosis of migraine headache per ichd-3 criteria * typical pattern of migraine attacks with approximately two migraines or more weekly * attacks are managed by means involving no more than twice weekly triptan use exclusion criteria: * axis i psychotic or manic disorder (e.g., schizophrenia, bipolar i, depression with psychosis) * axis i psychotic or manic disorder in first degree relative * unstable medical condition; severe renal, cardiac, or hepatic disease; pacemaker; or serious central nervous system pathology * pregnant, breastfeeding, lack of adequate birth control * history of intolerance to psilocybin, lysergic acid diethylamide (lsd), or related compounds * drug abuse within the past 3 months (excluding tobacco) * urine toxicology positive to drugs of abuse * alcohol use of \>21 drinks per week (males); \>14 drinks per week (females; niaaa guidelines) * use of alcohol in the week prior to the first test day * use of vasoconstrictive medications (i.e., sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days * use of serotonergic antiemetics (i.e., ondansetron) in the past 2 weeks * use of antidepressant medication (i.e., tca, maoi, ssri) in the past 6 weeks * use of steroids or certain other immunomodulatory agents (i.e., azathioprine) in the past 2 weeks * use of migraine onabotulinum toxin (i.e., botox) or monoclonal antibodies against cgrp or its receptor (i.e., erenumab) in the past month or while therapeutic effects are still present

Keywords: psilocybin inflammation calcitonin gene-related peptide (cgrp) pituitary adenylate cyclase-activating peptide (pacap)
an mhealth intervention to improve medication adherence and health outcomes

Conditions: Coronary Heart Disease

Summary: investigators evaluated the efficacy of a pilot-tested mhealth intervention to improving medication adherence and health outcomes among patients with coronary heart disease.

this was a two-arm parallel randomized controlled trial, in which 116 and 114 participants were assigned to the experimental and control groups, respectively. the mhealth intervention in this study had been pilot tested and tailored. specifically, the experimental group received a medication-taking reminder every morning via wechat app and educational materials of coronary heart disease and medication adherence every five days via message express app. the control group received only general educational materials, which were irrelevant to coronary heart disease or medication adherence, every 5 days via message express app. all participants were diagnosed with coronary heart disease. the specific recruitment criteria of participants had been published in peer-reviewed journal.

Eligibility criteria:
inclusion criteria: * (1) had a medical diagnosis of coronary heart disease; * (2) aged 18 years or older; * (3) had an antihypertensive medication regimen for 90 days or more from enrollment; * (4) able to read messages through mobile phone; * (5) had a mobile phone that could receive messages from wechat and reminders from message express; * (6) capable of giving his/her own consent; and * (7) had an electronic blood pressure cuff to check blood pressures and heart rates. exclusion criteria: * was enrolled in other research studies
program evaluating the autoimmune disease investigational drug ct-p13 in ra patients(planetra)

Conditions: Rheumatoid Arthritis

Summary: this is the trial to see how our product is similar to remicade by comparing the results of blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose and folic acid in rheumatoid arthritis patients who are not receiving adequate response to methotrexate alone up to week 30.


Eligibility criteria:
inclusion criteria: * diagnosed with active rheumatoid arthritis * at least 3 months of treatment with methotrexate exclusion criteria: * have allergies to infliximab * serious infection
treatment decision-making among patients diagnosed with papillary microcarcinoma and their significant others

Conditions: Thyroid Cancer; Papillary Microcarcinoma

Summary: the purpose of this study is to understand more about why some patients choose to have surgery to treat their papillary microcarcinoma (pmc) and others choose to have their papillary microcarcinoma (pmc) regularly watched by their doctor to see if and when they may need surgery (referred to as "active surveillance"). the investigators also hope learn more about what patients and their family members worry about or feel they will gain from surgery or active surveillance.


Eligibility criteria:
inclusion criteria: thyroid cancer patient eligibility will include: * thyroid cancer patients who have been diagnosed with papillary microcarcinoma (or subcentimeter thyroid lesions with fine needle aspiration biopsy suspicious for papillary or follicular thyroid cancer) within the prior 6-12 months as per emr path report and clinician assessment; * presented with the option of treating their papillary microcarcinomas with either surgery or active surveillance as per treating physician; * english-fluent; * 18 years of age or older; patient-designated significant other eligibility will include: * nomination by patient as individual who assisted patient in decision-making regarding how to treat thyroid papillary microcarcinoma; * english-fluent; * 18 years of age or older; exclusion criteria: thyroid cancer patient exclusion criteria will include: * thyroid cancer patients with known loco-regional or distant metastases prior to initial surgical intervention as per path report.

Keywords: focus group 11-108
study on the outcome of treatment of rotator cuff injury by ultrasound-guided injection

Conditions: Rotator Cuff Injury

Summary: rotator cuff injury is a common shoulder joint disease in clinic. if conservative treatment fails to improve pain symptoms and range of motion, the surgical indications are. numerous studies have shown that the pain of rotator cuff injury usually comes not from the broken tendon, but from periarthritis tendonitis, bursitis or adhesive shoulder capsule, etc. ultrasound-guided drug injection combined with conventional rehabilitation treatment can significantly improve the pain symptoms and increase joint mobility. this study intends to use prospective cohort study methods, exposed factors for ultrasound-guided injection drug treatment, establish a rotator cuff injury exposure group and the control group of shoulder joint dysfunction queue, whether of ultrasound guided drug injection therapy can increase the shoulder joint function analysis, and explore for the rotator cuff injury method provides the basis of the evidence-based conservative treatment. the establishment of a conservative treatment cohort for rotator cuff injury will also lay the foundation for the accurate rehabilitation treatment of rotator cuff injury.


Eligibility criteria:
inclusion criteria: * chief complaint around shoulder joint discomfort or restricted movement * nuclear magnetic or ultrasound in the diagnosis of rotator cuff injury and not to consider surgery patients * assessed by the musculoskeletal ultrasound images, diagnosed with tendonitis around shoulder joint, slippery bursa phlogistic or adhesive shoulder level * section capsule, such as indications of patients treated with ultrasound guided by injection. exclusion criteria: * history of shoulder fractures, open trauma, or surgery combined with shoulder and hand syndrome, gout, autoimmune arthritis, infectious arthritis, and other factors resulting in shoulder pain or limited mobility

Keywords: rotator cuff injury ultrasound-guided drug injection
cognitive and neural assessment platform and localized norm for macau older adults.

Conditions: Cognition Disorders in Old Age; Cognitive Decline; Cognitive Impairment; Cognitive Dysfunction; Cognitive Change; Aging

Summary: the current project is dedicated to creating a comprehensive cognitive and neural assessment platform and corresponding norms tailored specifically to the older adults in macau.

the investigators will establish this assessment platform using a combination of methods, including interviews, surveys, and expert reviews. steps include adapting existing assessment methods to the macau context, developing new cognitive and neural tasks, defining standardized procedures, seeking external expert input, conducting pilot tests, and validation processes, and refining both the platform and its accompanying manual.

Eligibility criteria:
inclusion criteria: * must be a local adult resident of macau * age above 50 years for older adult cohort * younger adults individuals above 18 will be included as control comparators exclusion criteria: * history of neurological injury or disease * current use of medications that affect brain function or blood flow * contraindications to mri scanning, such as the presence of an electric/mechanical implant or device (e.g., pacemaker) * claustrophobia * body weight over 300 lbs due to weight and physical constraints of the scanner (i.e., bore size limited to 55 cm) * inability to provide informed consent * pregnancy * being under the legal age of adulthood (children) * incarcerated individuals (prisoners)

Keywords: macau cognitive aging
treatment of pulmonary hypertension 1 study

Conditions: Pulmonary Arterial Hypertension

Summary: the objective of this study is to assess the safety, performance and initial effectiveness of the tivus™ system when used for pulmonary artery denervation through subjective and objective change in clinical parameters and haemodynamic evaluation. this is a prospective, multi-center, non-randomized, open-label clinical trail. the study will be conducted in up to 5 centers and will recruit up to 15 patients diagnosed with pah, functional class iii who have stable pah on a stable drug regimen of two pulmonary arterial hypertension specific medications.


Eligibility criteria:
inclusion criteria: * patient with known pulmonary arterial hypertension (pah), which has been diagnosed as idiopathic pah, connective tissue disease pah, anorexigen induced or familial pah * pah diagnosis confirmed by hemodynamic evaluation performed prior to screening and showing all of the following: mean pulmonary artery pressure (mpap) ≥25 mmhg at rest; pulmonary capillary wedge pressure (pcwp) or left ventricular end diastolic pressure (lvedp) ≤15 mmhg; pulmonary vascular resistance (pvr) at rest \>3 wood units; not meeting the criteria for a positive vasodilator response (fall in mpap ≥ 10 mmhg to ≤ 40 mmhg). * patient with a current diagnosis of who functional class iii * patient should be on two pulmonary arterial hypertension specific medications other than parenteral prostanoids * patient is adhering to a stable drug regimen (i.e., with no changes of dose or medication for a minimum of 3 months prior to enrollment) * patient with egfr levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂ 150µmol/l exclusion criteria: * patient who are treated with parenteral prostanoids * pregnant women or women planning a pregnancy within 12 months of study enrolment * patient with significant co-morbid conditions which, at the discretion of the pi, are deemed to prohibit study entry * patient with life expectancy of less than a year * concurrent enrollment in another device or drug trial except for observational studies (unless specifically approved by the sponsor) * patient with pulmonary artery anatomy that precludes treatment * patient with moderate to severe pulmonary artery stenosis * patient with any pulmonary artery aneurysm * patient who has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 6 months
evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation

Conditions: Lung Cancer

Summary: the goal clinical trial is to evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation in primary lung cancer and metastatic lung cancer. the main question it aims to answer are:evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation. participants will undergo percutaneous or transbronchial argon-helium cryoablation.


Eligibility criteria:
inclusion criteria: * primary or metastatic lung cancer with definite pathological diagnosis * not suitable for thoracotomy due to serious or serious lung or systemic diseases * peripheral lung cancer involves pleura and chest wall, and cannot be completely removed after surgery * there are indications for surgical resection, but the patient refuses to operate * single tumor, maximum diameter ≤ 5cm * or the number of tumors ≤ 3 and the maximum diameter ≤ 3cm * ecog-ps score ≤ 2 * the expected survival period is more than three months * those who have not participated in other clinical verifications within 3 months * subjects voluntarily signed the informed consent form exclusion criteria: * serious cardio-cerebral disease or other mental diseases * severe pulmonary fibrosis, especially drug-induced pulmonary fibrosis * patients with previous severe pulmonary dysfunction, pulmonary ventilation disorder and multiple pulmonary bullae * have a history of immunodeficiency, including hiv test (enzyme-linked immunosorbent assay and western blotting) positive * chemotherapy, radiotherapy, interventional therapy, ablation and surgical treatment within 30 days before surgical treatment * there is a tendency to severe bleeding, and the platelet is less than 50 × 109/l and severe disorder of coagulation function * coagulation index (pt, tt, aptt)\>2.5 times of the upper normal limit * malignant pleural effusion on the same side of the ablation focus was not well controlled * poor general condition, multiple organ failure, cachexia, severe anemia and nutritional metabolism disorder * those who have extensive extrapulmonary metastasis and are not suitable for ablation treatment * those who often use sedatives, sleeping pills, tranquilizers or other addictive drugs * pregnant or lactating women * those who can not judge the curative effect * other conditions determined by the researcher to be unsuitable for the group, such as inability to tolerate cryoablation, difficulty in follow-up, and other serious diseases
the gene expression patterns in the peripheral white blood cells of type 2 diabetic patients

Conditions: Diabetes Mellitus, Type 2; Atherosclerosis

Summary: the investigators hypothesize that macrophages play a crucial role in the pathogenesis of atherosclerosis in patients with type 2 diabetes mellitus (t2dm).

cardiovascular events are the leading cause of death in developed countries worldwide, including taiwan. type 2 diabetes mellitus (t2dm), previously considered merely as one of the risk factors, has been recently unanimously accepted to be coronary artery disease-equivalent. how t2dm may lead to accelerated atherosclerosis remains obscure. hyperglycemia with or without hyperinsulinemia may lead to higher oxidative stress and generalized inflammation. the oxidative stress and inflammation may play a significant role in the pathogenesis in diabetic complications, including micro- and macro-vascular complications. macrophages together with t-lymphocytes are the earliest cell-types found in fatty-streaks, the earliest atherosclerotic lesions. macrophages are also well known cellular mediators of oxidative stress and inflammation. therefore, it is plausible to hypothesize that macrophages play a crucial role in the pathogenesis of atherosclerosis in patients with t2dm. in addition, the other cell types of the peripheral white blood cells (wbc), such as neutrophils, have been shown to be intimately related to acute coronary syndrome. therefore, the study on the biology of peripheral wbcs may tell us something about the pathophysiology of diabetic macro-vascular complications. methods: 1. normal control: fasting plasma glucose (fpg) less than 126 mg/dl. 2. t2dm: fpg \>＝126 mg/dl. * group 1 (good glycemic control): hemoglobin a1c (hba1c) \<＝ 7% in the past 6 months * group 2 (poor glycemic control): hba1c \>＝ 8% in the past 6 months 3. blood sample will be collected at baseline and after aggressive control.

Eligibility criteria:
inclusion criteria: * normal control: fasting plasma glucose (fpg) less than 126 mg/dl. * t2dm: fpg \>＝126 mg/dl. * group 1 (good glycemic control): hba1c\<＝7% in the past 6 months * group 2 (poor glycemic control): hba1c\>＝8% in the past 6 months exclusion criteria: * acute systemic diseases

Keywords: diabetes mellitus monocyte gene expression monocyte gene expression